Cytek Biosciences Management
Management criteria checks 2/4
Cytek Biosciences' CEO is Wenbin Jiang, appointed in Dec 2014, has a tenure of 10.83 years. total yearly compensation is $6.08M, comprised of 9.8% salary and 90.2% bonuses, including company stock and options. directly owns 4.18% of the company’s shares, worth $21.10M. The average tenure of the management team and the board of directors is 3.5 years and 3.8 years respectively.
Key information
Wenbin Jiang
Chief executive officer
US$6.1m
Total compensation
| CEO salary percentage | 9.85% |
| CEO tenure | 10.8yrs |
| CEO ownership | 4.2% |
| Management average tenure | 3.5yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Cytek Biosciences: Growth Over Profit Will Pay Off In The Long Term
Sep 09Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Aug 15
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 28
APAC Markets And Recurring Revenues Will Support Life Sciences
Growth in Asia-Pacific and strong recurring revenues from services and reagents offset weaker performance in the US and Europe, supporting long-term stability.The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31%
May 30Why Cytek Biosciences Should Beat Q1 Earnings Expectations
Apr 28Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt?
Apr 16Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 13Upgrading Cytek Biosciences Stock On An Upcoming Catalyst
Jan 09Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
Dec 16Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Nov 07Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$6m |
| Mar 31 2025 | n/a | n/a | -US$11m |
| Dec 31 2024 | US$6m | US$599k | -US$6m |
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | US$5m | US$578k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$4m | US$524k | US$3m |
| Sep 30 2022 | n/a | n/a | -US$901k |
| Jun 30 2022 | n/a | n/a | -US$3m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | US$5m | US$375k | US$52k |
| Sep 30 2021 | n/a | n/a | US$575k |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$422k | US$241k | US$3m |
Compensation vs Market: Wenbin's total compensation ($USD6.08M) is above average for companies of similar size in the US market ($USD2.32M).
Compensation vs Earnings: Wenbin's compensation has increased whilst the company is unprofitable.
CEO
Wenbin Jiang (61 yo)
Dr. Wenbin Jiang, Ph D., is co-founder, Chairman and President of Cytek Biosciences, Inc and has been its Chief Executive Officer and Director since December 2014. Dr. Jiang is a seasoned entrepreneur and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$6.08m | 4.18% $ 21.1m | |
| Chief Financial Officer | 1.6yrs | US$1.77m | 0.053% $ 268.2k | |
| CTO & Director | 10.8yrs | US$1.86m | 4.76% $ 24.0m | |
| Chief Legal Officer & Corporate Secretary | 4.8yrs | US$2.41m | 0.078% $ 393.6k | |
| Senior Vice President of Global Sales & Services | 2.2yrs | US$1.00m | 0.018% $ 93.0k | |
| Head of Corporate Development Analytics | 1.6yrs | US$758.17k | 0.050% $ 252.5k |
Experienced Management: CTKB's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$6.08m | 4.18% $ 21.1m | |
| CTO & Director | 10.8yrs | US$1.86m | 4.76% $ 24.0m | |
| Lead Independent Director | 3.3yrs | US$244.99k | 0.012% $ 62.4k | |
| Independent Director | 7.1yrs | US$284.99k | 0.034% $ 169.6k | |
| Independent Director | 1.3yrs | US$340.00k | 0.0080% $ 40.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.8yrs | US$244.28k | 0.012% $ 62.4k | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
Experienced Board: CTKB's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 15:10 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytek Biosciences, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |
| Yuko Oku | Morgan Stanley |